Dexmedetomidine and Blood Coagulation

Seoul National University

Status: Completed

Conditions: Blood Coagulation Disorder

Treatments: Drug: 0.25 ul of dexmedetomidine; Drug: 0.75 ul of dexmedetomidine; Drug: 0.5 ul of dexmedetomidine; Drug: 0 ul of dexmedetomidine

Study type: Observational

Funder types: Other

Identifiers

NCT04269278

B-2002/595-301

Details and patient eligibility

About

Dexmedetomidine may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of dexmedetomidine. The investigators have therefore performed the present study to measure the effect of dexmedetomidine on the coagulation pathway according to the drug concentration level using a rotational thromboelastometry test.

Enrollment: 11 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers
• Age: 20 to 65 years
• Body weight > 50 kg
• Volunteers who provided informed consent

Exclusion criteria

• Hematologic disease
• Anticoagulant medication

Trial design

11 participants in 4 patient groups

0 ng/ml

Description:

Blood specimen which was added 0 ul of dexmedetomidine

Treatment:

Drug: 0 ul of dexmedetomidine

0.5 ng/ml

Description:

Blood specimen which was added 0.25 ul of dexmedetomidine

Treatment:

Drug: 0.25 ul of dexmedetomidine

1.0 ng/ml

Description:

Blood specimen which was added 0.5 ul of dexmedetomidine

Treatment:

Drug: 0.5 ul of dexmedetomidine

1.5 ng/ml

Description:

Blood specimen which was added 0.75 ul of dexmedetomidine

Treatment:

Drug: 0.75 ul of dexmedetomidine